HAVN Life Sciences Inc. — Share Issue/Capital Change 2021

Jan 23, 2021

==> picture [288 x 66] intentionally omitted <==

Havn Life Grants Stock Options and Restricted Share Rights

January 22, 2021

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the

“Company” or “Havn Life”) announces that it has granted 250,000 incentive stock options (the “Options”) at an exercise price of $0.85 per common share for a five year term.

Further, the Company has granted 50,000 restricted share rights (the “RSRs”) with a one-eight (1/8[th] ) of the RSRs to vest every three months beginning April 21, 2021.

The Options and RSRs were granted to a director of the Company under the Company’s Equity Incentive Plan.

The Company also announces that it has issued an aggregate of 384,896 common shares (the “Common Shares”) at a deemed price of $0.96 per Common Share in the capital of the Company to certain consultants of the Company for past services rendered to the Company.

On Behalf of The Board of Directors

Tim Moore Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram, and Youtube

==> picture [22 x 22] intentionally omitted <==

==> picture [22 x 22] intentionally omitted <==

==> picture [22 x 22] intentionally omitted <==

Contact:

Investor Relations: ir@havnlife.com 604 687 7130 Media: savi@emergence-creative.com 647 896-8078

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in

==> picture [36 x 31] intentionally omitted <==

this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

==> picture [36 x 31] intentionally omitted <==